Barriers for the development, translation, and implementation of nanomedicine: an African perspective

Nanotechnology is a branch of science, which empowers innovation to discover new medical technologies, improving current diagnostic and treatment methods. The scope of nanotechnology focuses mainly on “technology transfer”, in which research aims to facilitate the application of recent nanoscience techniques to conventional medicine development methodologies. Nanomedicine is attractive to researchers who wish to target specific infectious diseases associated with poverty, which is highlighted through the many pertinent examples of recent breakthroughs in nanomedicine. An overview is provided in this study to highlight the barriers and implementation of nanomedicine for various infectious diseases in the African continent. Patient backgrounds provide the greatest of challenges for new technologies in terms of improving bioavailability and dosage. This review points out the current situation of nanomedicine in Africa and explores the possibility of how nanomedicine could improve patient drug regimens and wellbeing.

[1]  M. Saravanan,et al.  Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV). , 2018, Pharmaceutical nanotechnology.

[2]  David M. Brown,et al.  Mechanism of neutrophil activation and toxicity elicited by engineered nanomaterials. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  N Hussain,et al.  Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. , 2001, Advanced drug delivery reviews.

[4]  Thomas J Webster,et al.  Nanomedicine: what’s in a definition? , 2006, International journal of nanomedicine.

[5]  Hak-Kim Chan,et al.  Nanodrugs: pharmacokinetics and safety , 2014, International journal of nanomedicine.

[6]  Pericles Pericleous,et al.  Quantum dots hold promise for early cancer imaging and detection , 2012, International journal of cancer.

[7]  S. P. Akpabio.  World Health Organisation , 1983, British Dental Journal.

[8]  N. Durán,et al.  Nanopharmaceuticals as a solution to neglected diseases: Is it possible? , 2017, Acta tropica.

[9]  Tamer M Samir,et al.  Unmodified gold nanoparticles for direct and rapid detection of Mycobacterium tuberculosis complex. , 2013, Clinical biochemistry.

[10]  Rajshri M Navalakhe,et al.  Application of nanotechnology in biomedicine. , 2007, Indian journal of experimental biology.

[11]  Andrew Owen,et al.  The Application of Nanotechnology to Drug Delivery in Medicine , 2015 .

[12]  Michael Hay,et al.  Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.

[13]  I. G. Meerovich,et al.  Influence of Liposome Size on Accumulation in Tumor and Therapeutic Efficiency of Liposomal Near-IR Photosensitizer for PDT based on Aluminum hydroxide tetra-3-phenylthiophthalocyanine , 2008 .

[14]  M. Busquets,et al.  Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents , 2015, International journal of nanomedicine.

[15]  O. Neyrolles,et al.  Zinc and copper toxicity in host defense against pathogens: Mycobacterium tuberculosis as a model example of an emerging paradigm , 2013, Front. Cell. Infect. Microbiol..

[16]  Marilena Loizidou,et al.  Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.

[17]  S. Choudhary,et al.  Potential of nanotechnology as a delivery platform against tuberculosis: current research review. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[18]  H. Barabadi.  Nanobiotechnology: A promising scope of gold biotechnology. , 2017, Cellular and molecular biology.

[19]  Curtis Larimer,et al.  Antimycobacterial efficacy of silver nanoparticles as deposited on porous membrane filters. , 2013, Materials science & engineering. C, Materials for biological applications.

[20]  H. Car,et al.  Magnetic nanoparticles as new diagnostic tools in medicine. , 2012, Advances in medical sciences.

[21]  M. Gramiccia,et al.  Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Keith Guy,et al.  The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. , 2008, Toxicology and applied pharmacology.

[23]  Caragh S Murphy,et al.  Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. , 2011, Colloids and surfaces. B, Biointerfaces.

[24]  Arthur G Erdman,et al.  The big picture on nanomedicine: the state of investigational and approved nanomedicine products. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[25]  Cristina Fornaguera,et al.  Personalized Nanomedicine: A Revolution at the Nanoscale , 2017, Journal of personalized medicine.

[26]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[27]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[28]  Darren L. Smith,et al.  Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies , 2016, Nature Communications.

[29]  Ameer Azam,et al.  Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: a comparative study , 2012, International journal of nanomedicine.

[30]  M. Saravanan,et al.  Anti-cancer green bionanomaterials: present status and future prospects , 2017 .

[31]  Dong Soo Lee,et al.  Nanomedicine: Past, present and future - A global perspective. , 2015, Biochemical and biophysical research communications.

[32]  A. Fontes,et al.  Semiconductor fluorescent quantum dots: efficient biolabels in cancer diagnostics. , 2009, Methods in molecular biology.

[33]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[34]  Pedro M. Valencia,et al.  Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .

[35]  Mary E Napier,et al.  More effective nanomedicines through particle design. , 2011, Small.

[36]  Helinor J Johnston,et al.  Toxicological effect of engineered nanomaterials on the liver , 2014, British journal of pharmacology.

[37]  R. Fernandez,et al.  Recognition of lipid A variants by the TLR4-MD-2 receptor complex , 2012, Front. Cell. Inf. Microbio..

[38]  P. McCarron,et al.  Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. , 2008, Bioconjugate chemistry.